About: Mohamed El Kassas

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mohamed El Kassas Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) 研究者 (zh) հետազոտող (hy)
rdfs:label	Mohamed El Kassas (en) Mohamed El Kassas (es) Mohamed El Kassas (nl) Mohamed El Kassas (sl) Mohamed El Kassas (ast)
skos:prefLabel	Mohamed El Kassas (en) Mohamed El Kassas (es) Mohamed El Kassas (nl) Mohamed El Kassas (sl) Mohamed El Kassas (ast)
name	Mohamed El Kassas (en) Mohamed El Kassas (es) Mohamed El Kassas (nl) Mohamed El Kassas (sl) Mohamed El Kassas (ast)
Scopus author ID	wds:Q54218237-9154D95F-3161-4959-90B8-D17F8A55918C
Scopus author ID	26323643100
given name	wds:Q54218237-244E6763-298F-47E4-9E1F-0A73264C5D98
given name	Mohamed
instance of	wds:Q54218237-1CBA8FD9-BF43-40E1-AC3D-6A9ECC8D6CAD
instance of	Homo sapiens
Loop ID	wds:Q54218237-1F6AF533-5ADF-446D-A06B-6C672CFAC207
Loop ID	957037
occupation	wds:Q54218237-4890EF01-DEE9-47AF-9C8F-7ABB751DDD0F
sex or gender	wds:Q54218237-F8CD2153-365F-4180-8A2A-A3B6D2EBF0C3
on focus list of Wikimedia project	wds:Q54218237-B93C019C-4ABB-49C2-98BD-35F6944892F0
family name	wds:Q54218237-F67C71E2-8214-4ED8-ABDC-8A89BB3FF128
occupation	researcher
sex or gender	male
on focus list of Wikimedia project	WikiProject COVID-19
family name	Kassas
ORCID iD	wds:Q54218237-065C08AC-0BDF-45BD-A04C-3FEE520872A6
ORCID iD	https://orcid.org/0000-0002-3396-6894
ORCID iD	0000-0002-3396-6894
ResearcherID	wds:Q54218237-66324877-1BAE-4025-B440-6C587578AB8E
ResearcherID	F-8306-2019
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q54218237
is author of	Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. New era for management of chronic hepatitis C virus using direct antiviral agents: A review Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. The future for the treatment of genotype 4 chronic hepatitis C. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves Emergency endoscopic variceal band ligation in a COVID-19 patient presented with hematemesis while on mechanical ventilation Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Percutaneous Ultrasound-Guided Fine Needle Aspiration in Diagnosis of Focal Pancreatic Masses Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Diabetes Association with Liver Diseases: An Overview for Clinicians Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease Chitinase 3- like 1, Tolloid-like Protein 1 and Intergenic Gene Polymorphisms are Predictors for Hepatocellular Carcinoma Development after HCV Eradication by Direct-Acting Antivirals Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Five Fibrosis Biomarkers Together with Serum Ferritin Level to Diagnose Liver Fibrosis and Cirrhosis MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection. Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series. Correction to: Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. Safety of direct antiviral agents in the management of hepatitis C. A new potent NS5A inhibitor in the management of hepatitis C virus: ravidasvir. Microwave ablation in the spleen versus partial splenic artery embolisation: A new technique for hypersplenism in cirrhosis. How to optimize HCV therapy in genotype 4 patients. Egyptian liver library: Rebuilding the pyramid of liver disease evidence in Egypt. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From Egypt After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt Egyptian liver library: An indexed database for liver disease evidence in Egypt Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD) Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients HCV in Egypt, prevention, treatment and key barriers to elimination Managing diabetes and liver disease association
is author of	wds:Q92523327-F573BC21-06D8-40B6-BD2F-0E70627E8DEE wds:Q30238676-EBD5B580-4EE4-4559-9A63-5B0C7C8B4F15 wds:Q33772939-63457B77-4D54-484F-A2B9-16CDC9904198 wds:Q38991020-126829CF-2522-415A-B6D5-AED5013F8040 wds:Q47550461-AF24B35B-4D6E-4AA2-A9FD-05B2266DC782

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software